keyword
MENU ▼
Read by QxMD icon Read
search

Breast endocrine surgery

keyword
https://www.readbyqxmd.com/read/28205042/screening-relevant-age-threshold-of-70%C3%A2-years-and-older-is-a-stronger-determinant-for-the-choice-of-adjuvant-treatment-in-breast-cancer-patients-than-tumor-biology
#1
E C Inwald, O Ortmann, M Koller, F Zeman, F Hofstädter, M Evert, G Brockhoff, M Klinkhammer-Schalke
PURPOSE: The 70-year threshold determines whether patients are eligible or not for the breast cancer screening program in Germany. It is not known whether this age threshold also influences the choice of adjuvant treatment and ultimate outcome. METHODS: 3463 patients were analyzed from the clinical cancer registry Regensburg (Germany) with primary, non-metastatic invasive breast cancer diagnosed between 2000 and 2012. The distribution of tumor biological subtypes was evaluated in breast cancer patients both in those eligible for screening (ESG, 50-69 years) and those not eligible for screening (NESG, ≥70 years)...
February 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28193310/depressive-symptoms-and-inflammation-are-independent-risk-factors-of-fatigue-in-breast-cancer-survivors
#2
C Xiao, A H Miller, J Felger, D Mister, T Liu, M A Torres
BACKGROUND: Psychosocial and inflammatory factors have been associated with fatigue in breast cancer survivors. Nevertheless, the relative contribution and/or interaction of these factors with cancer-related fatigue have not been well documented. METHOD: This cross-sectional study enrolled 111 stage 0-III breast cancer patients treated with breast surgery followed by whole breast radiotherapy. Fatigue was measured by the total score of the Multidimensional Fatigue Inventory-20...
February 14, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/28176908/primary-neuroendocrine-breast-carcinomas-a-retrospective-analysis-and-review-of-literature
#3
Xin Yang, Youde Cao, Chen Chen, Lin Liu, Cheng Wang, Shengchun Liu
BACKGROUND: Primary neuroendocrine breast carcinomas (NEBCs) are a rare type of breast carcinomas that lack comprehensive recognition, including the clinicopathological features, therapeutic strategies, and prognostic significance. The aim of this retrospective analysis is to present and analyze our own data of primary NEBCs. MATERIALS AND METHODS: We retrospectively reviewed the medical records from 2005 to 2015 in The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China to obtain a cohort of breast carcinoma patients who were confirmed to have primary NEBC by histopathology...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28164759/neoadjuvant-therapy-for-her2-positive-breast-cancer
#4
Rachel Wuerstlein, Nadia Harbeck
In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and -depending on the tumor biology - endocrine adjuvant therapy, and ultimately follow up. 10-year survival rates in the HER2-positive subgroup of breast cancer do reach now more than 75% with the introduction of first adjvuant and later neoadjuvant HER2-targeted therapies over the last 15 years...
February 2, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28155606/clinical-utility-of-neoadjuvant-endocrine-therapy-for-hormone-receptor-positive-breast-cancer
#5
Hans-Christian Kolberg, Bahriye Aktas, Cornelia Liedtke
Primary endocrine therapy is an option in cases of hormone receptor positive and HER2 negative non-metastatic breast cancer. Aromatase inhibitors are considered therapy of choice in postmenopausal patients. In premenopausal patients aromatase inhibitors in combination with LHRH-analogues are regarded superior to tamoxifen. Three different settings have to be discriminated: • Patients too frail for surgery are candidates for primary endocrine therapy in order to control the disease. Treatment duration is determined by the course of the disease...
February 1, 2017: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/28152911/benchmarks-of-quality-breast-care-over-10-years
#6
F Lee Tucker, Barbara Rabinowitz, Teresa Heckel, Jennifer S Gass
: 272 Background: In 2005, the National Quality Measures for Breast Centers (NQMBC) was initiated as a web-based program to capture breast center performance using process of care measurements. The program participant enters data verified by the breast center director or administrator which was randomly audited. As a center submits data, their results are immediately compared with other similar centers as well as with all submitting centers. METHODS: Of the 31 measures, we focus on six pertinent measures of quality breast care; time from diagnostic mammogram to needle biopsy, time from needle biopsy to initial breast cancer surgery, breast conservation rate, use of radiation therapy for breast conserving patients, use of endocrine therapy, and use of chemotherapy...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152150/evaluation-of-the-quality-of-adjuvant-endocrine-therapy-delivery-for-breast-cancer-care-in-the-united-states
#7
Bobby Daly, Olufunmilayo I Olopade, Ningqi Hou, Katharine Yao, David J Winchester, Dezheng Huo
Importance: Randomized trials in breast cancer have demonstrated the clinical benefits of adjuvant endocrine therapy (AET) in preventing recurrence and death. The examination of concordance with AET guidelines at a national level as a measure of quality of care is important. Objective: To investigate temporal trends and factors related to receipt of AET for breast cancer. Design, Setting, and Participants: This retrospective cohort study included 981 729 women with breast cancer in the National Cancer Database from January 1, 2004, to December 31, 2013...
February 2, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28133341/-two-cases-of-lung-metastasis-from-breast-cancer-successfully-treated-with-endocrine-therapy
#8
Kumi Hasegawa, Yasuhiro Higashi, Ayako Kamiya, Yasushi Takatsuno, Ito Kondo, Jun Kaneko, Takeshi Endo, Shizuaki Maejima
We report 2 cases of lung metastasis from breast cancer that were successfully treated with endocrine therapy.Case 1 is a 69-year-old woman with cirrhosis of the liver caused by hepatitis C.She underwent surgery for left breast cancer at the age of 58, and surgery for right breast cancer at the age of 65.Four years later, she was diagnosed with lung metastasis of breast cancer.She received letrozole and the treatment was effective.Because the severity of the pleural effusion increased 3 years later, fulvestrant was subsequently administered...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133287/-a-study-of-patients-who-underwent-breast-conserving-surgery-and-developed-cryptogenic-organizing-pneumonia-cop
#9
Soichiro Ueno, Takashi Nakakuma, Osamu Murata, Norihiko Sengoku, Kazuhiro Karikomi, Megumi Honma
Of the 210 patients who underwent breast-conserving surgery for breast cancer and received radiation therapy for 3 years from April 2012 to March 2015 at the Department of Therapeutic Radiology of our hospital, 6 were diagnosed with cryptogenic organizing pneumonia(COP)-like pneumonia and treated as reported. The mean age of the patients was 51years(40- 65 years), and the pathological subtypes were the luminal type(5 cases)and HER2 type(1case ), all of which were treated with radiation therapy for breast conservation...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133214/-a-case-of-local-recurrence-after-conserving-therapy-for-occult-breast-cancer-with-immediate-breast-reconstruction
#10
Junichi Inatome, Chiyomi Egawa, Teruaki Nagano, Shinichi Nakatsuka, Takuya Sakamoto, Kohei Murakami, Atsushi Naito, Yoshiteru Katsura, Yoshiaki Ohmura, Yoshinori Kagawa, Atsushi Takeno, Yutaka Takeda, Takeshi Kato, Shigeyuki Tamura, Yuichi Takatsuka
We report the case of a 70-year-oldwoman with local recurrence of occult breast cancer after conserving therapy. Breast cancer metastasis to an axillary lymph node was suspected when she was 62-years-old. Even with mammography, ultrasound sonography, positron emission tomography/computedtomography, andmagnetic resonance imaging, the primary disease lesion could not be identified. She underwent axillary dissection, and received 5 years of endocrine therapy. Eight years after surgery, a new ipsilateral breast tumor was detectedusing ultrasoundsonography andvacuum assistedbiopsy, confirmedas invasive carcinoma...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133206/-difficult-decision-about-a-surgical-margin-for-a-non-invasive-apocrine-carcinoma-in-the-breast-report-of-a-case
#11
Tomohiro Hirano, Kenichi Sakurai, Shigeru Fujisaki, Keita Adachi, Shuhei Suzuki, Yuki Masuo, Saki Nagashima, Yukiko Hara, Katsuhisa Enomoto, Ryouichi Tomita, Kenji Gonda
We report a case of non-invasive apocrine carcinoma. In this case, we could not identifythe surgical margin. The patient was 39-year-old woman. Micro calcifications were discovered on her right breast during breast cancer screening. Stereotactic vacuum assisted core needle biopsywas performed and the pathological diagnosis was sclerosing adenosis. A low echoic lesion, 26mm in diameter, was discovered in the CDE area of her left breast byultrasonography . A contrast enhanced MRI showed a high intensityarea, 26mm in diameter, on her left breast...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133021/-breast-cancer-with-microinvasion-and-lymph-node-metastasis-diagnosed-by-microdochectomy-report-of-a-case
#12
Kenichi Sakurai, Shigeru Fujisaki, Keita Adachi, Shuhei Suzuki, Yuki Masuo, Saki Nagashima, Yukiko Hara, Tomohiro Hirano, Katsuhisa Enomoto, Ryouichi Tomita, Kenji Gonda
We report a case of breast cancer with microinvasion and lymph node metastasis. The patient was a 72-year-old woman who had spontaneous nipple discharge from her left breast. There was no detectable lesion on mammographyor duct endoscopy. Ultrasonography showed a low echoic lesion, 23×15mm in diameter, in the CD area of her left breast. Contrastenhanced MRI showed a high intensityarea, 25mm in diameter, in her left breast, so microdochectomywas performed. The histopathological diagnosis was invasive ductal carcinoma(invasion of 2mm)and the surgical margin was positive...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28112739/acquired-cyp19a1-amplification-is-an-early-specific-mechanism-of-aromatase-inhibitor-resistance-in-er%C3%AE-metastatic-breast-cancer
#13
Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, Giacomo Corleone, Sonia Fabris, Hermannus Kempe, Pernette J Verschure, Iros Barozzi, Valentina Vircillo, Sung-Pil Hong, Ylenia Perone, Massimo Saini, Andreas Trumpp, Giuseppe Viale, Antonino Neri, Simak Ali, Marco Angelo Colleoni, Giancarlo Pruneri, Saverio Minucci
Tumor evolution is shaped by many variables, potentially involving external selective pressures induced by therapies. After surgery, patients with estrogen receptor (ERα)-positive breast cancer are treated with adjuvant endocrine therapy, including selective estrogen receptor modulators (SERMs) and/or aromatase inhibitors (AIs). However, more than 20% of patients relapse within 10 years and eventually progress to incurable metastatic disease. Here we demonstrate that the choice of therapy has a fundamental influence on the genetic landscape of relapsed diseases...
January 23, 2017: Nature Genetics
https://www.readbyqxmd.com/read/28105873/loco-regional-morbidity-after-breast-conservation-and-axillary-lymph-node-dissection-for-early-breast-cancer-with-or-without-regional-nodes-radiotherapy-perspectives-in-modern-breast-cancer-treatment-the-skagen-trial-1-is-active
#14
Hanne Melgaard Nielsen, Rasmus Blechingberg Friis, Søren Linnet, Birgitte Vrou Offersen
BACKGROUND: Axillary lymph node dissection (ALND) and adjuvant radiotherapy (RT) in early breast cancer are associated with a risk of morbidity, including lymphedema and impaired shoulder mobility. The aim of this study was to evaluate loco-regional morbidity after breast conserving surgery (BCS), ALND, taxane-based chemotherapy and whole breast irradiation (WBI) with or without regional nodes RT. MATERIAL AND METHODS: Eligible patients had BCS and ALND from 2007 to 2012 followed by adjuvant taxane-based chemotherapy and if indicated, trastuzumab and endocrine treatment...
January 20, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28087099/prognostic-and-predictive-indicators-in-early-stage-breast-cancer-and-the-role-of-genomic-profiling-focus-on-the-oncotype-dx-%C3%A2-breast-recurrence-score-assay
#15
E Curtit, L Mansi, Y Maisonnette-Escot, J-L Sautière, X Pivot
Although useful prognostic and predictive insights can be gained from patient and tumour characteristics in early-stage breast cancer, it is not always straightforward to predict the likely risk of recurrence for each individual patient following breast surgery. One of the most difficult challenges faced by clinicians is identifying patients who may benefit most from adjuvant chemotherapy, and distinguishing these cases from those where endocrine therapy may be sufficient for cure. Genomic tests such as the Oncotype DX(®) Breast Recurrence Score(®) Assay have been developed to provide a robust and clinically validated assessment of a patient's individual tumour signature...
December 14, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28057031/-18-fdg-pet-ct-for-predicting-the-outcome-in-er-her2-breast-cancer-patients-comparison-of-clinicopathological-parameters-and-pet-image-derived-indices-including-tumor-texture-analysis
#16
David Groheux, Antoine Martineau, Luis Teixeira, Marc Espié, Patricia de Cremoux, Philippe Bertheau, Pascal Merlet, Charles Lemarignier
BACKGROUND: This study investigated the value of some clinicopathological parameters and 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)FDG-PET/CT) indices, including textural features, to predict event-free survival (EFS) in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) locally advanced breast cancer (BC) patients. METHODS: FDG-PET/CT indices and clinicopathological parameters were assessed before neoadjuvant chemotherapy (NAC)...
January 5, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28024968/assessing-the-variability-in-insurance-coverage-transparency-for-male-sexual-health-conditions-in-the-united-states
#17
Brian V Le, Sarah McAchran, David Paolone, Daniel R Gralneck, Daniel Williams, Wade Bushman
OBJECTIVES: To determine the degree of transparency of health insurer policies regarding coverage of male sexual health conditions, we examined the publicly available policy coverage documents of the largest US medical insurance plans. METHODS: We selected two index patients across the male sexual health spectrum: (1) a PDE5 refractory erectile dysfunction patient requiring intracavernosal injection therapy or penile prosthesis, (2) a 50 yo male patient with laboratory-confirmed, symptomatic hypogonadism requiring testosterone replacement therapy as defined by endocrine society criteria...
December 23, 2016: Urology
https://www.readbyqxmd.com/read/28002848/multidisciplinary-approach-to-neoadjuvant-endocrine-therapy-in-breast-cancer-a-comprehensive-review
#18
Tomás Reinert, Susana Ramalho, Rodrigo Gonçalves, Carlos Henrique Barrios, Marcia Silveira Graudenz, José Bines
Breast cancer is the most common type of cancer and the leading cause of cancer-related death among women worldwide. Hormone receptor-positive (HR+) tumors represent the most common form of this disease, with more than 70% of breast cancers expressing these receptors. Response and benefit to neoadjuvant chemotherapy (NCT) varies according to HR expression, with lower responses in luminal tumors as compared with hormone receptor-negative (HR-) and human epidermal growth factor receptor 2-positive (HER2+) tumors...
December 2016: Revista Brasileira de Ginecologia e Obstetrícia
https://www.readbyqxmd.com/read/28000325/breast-conservation-in-ductal-carcinoma-in-situ-dcis-what-defines-optimal-margins
#19
REVIEW
Michael S Toss, Sarah E Pinder, Andrew R Green, Jeremy Thomas, David A L Morgan, John F R Robertson, Ian O Ellis, Emad A Rakha
The introduction of mammographic screening has resulted in a rise in the detection rate of ductal carcinoma in situ (DCIS), currently accounting for one-fifth of screen-detected breast cancers. Although 60-70% of DCIS are treated with breast-conserving surgery (BCS) with or without radiotherapy, the frequency of subsequent surgery to re-excise positive margins in order to reduce the probability of recurrences remains high. DCIS recurrence is associated not only with financial, health and psychological implications; approximately half these recurrences are invasive disease...
November 7, 2016: Histopathology
https://www.readbyqxmd.com/read/27919974/a-phase-ii-study-of-adjuvant-chemotherapy-of-tegafur-uracil-for-patients-with-breast-cancer-with-her2-negative-pathologic-residual-invasive-disease-after-neoadjuvant-chemotherapy
#20
Satoru Tanaka, Mitsuhiko Iwamoto, Kosei Kimura, Yuko Takahashi, Hiyoya Fujioka, Nayuko Sato, Risa Terasawa, Kanako Kawaguchi, Ayana Ikari, Tomo Tominaga, Saki Maezawa, Nodoka Umezaki, Junna Matsuda, Kazuhisa Uchiyama
BACKGROUND: There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. PATIENTS AND METHODS: We treated patients with 270 mg/m(2) UFT per day for 2 years after definitive surgery and radiotherapy, if necessary...
2016: Anticancer Research
keyword
keyword
121072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"